ALKERMES | ALKS - Debt


ALKERMES reported $1.58B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Malin Corporation EUR 100K 0 Dec/2023
Merck USD 49.12B 222M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Otsuka Holdings JPY 227.98B 16.47B Dec/2025
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 63.73B 231M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026